|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0030705,
umls-concept:C0036525,
umls-concept:C0040083,
umls-concept:C0123931,
umls-concept:C0185117,
umls-concept:C0332281,
umls-concept:C0671970,
umls-concept:C0871261,
umls-concept:C1522484,
umls-concept:C1527249,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911684,
umls-concept:C2911692
|
|
pubmed:issue |
25
|
|
pubmed:dateCreated |
2006-8-31
|
|
pubmed:abstractText |
To evaluate the clinical activity and toxicity of capecitabine plus irinotecan as first-line therapy for patients with metastatic colorectal cancer (mCRC), and to describe the association of expression of thymidine phosphorylase (TP), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) with antitumor activity.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4069-77
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16943524-Adult,
pubmed-meshheading:16943524-Aged,
pubmed-meshheading:16943524-Aged, 80 and over,
pubmed-meshheading:16943524-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16943524-Camptothecin,
pubmed-meshheading:16943524-Colorectal Neoplasms,
pubmed-meshheading:16943524-Deoxycytidine,
pubmed-meshheading:16943524-Dihydrouracil Dehydrogenase (NADP),
pubmed-meshheading:16943524-Disease-Free Survival,
pubmed-meshheading:16943524-Feasibility Studies,
pubmed-meshheading:16943524-Female,
pubmed-meshheading:16943524-Fluorouracil,
pubmed-meshheading:16943524-Gene Expression Regulation, Enzymologic,
pubmed-meshheading:16943524-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:16943524-Humans,
pubmed-meshheading:16943524-Immunohistochemistry,
pubmed-meshheading:16943524-Logistic Models,
pubmed-meshheading:16943524-Male,
pubmed-meshheading:16943524-Middle Aged,
pubmed-meshheading:16943524-Neoplasm Staging,
pubmed-meshheading:16943524-Predictive Value of Tests,
pubmed-meshheading:16943524-Proportional Hazards Models,
pubmed-meshheading:16943524-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:16943524-Survival Analysis,
pubmed-meshheading:16943524-Thymidine Phosphorylase,
pubmed-meshheading:16943524-Thymidylate Synthase,
pubmed-meshheading:16943524-Treatment Outcome,
pubmed-meshheading:16943524-Tumor Markers, Biological
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
|
|
pubmed:affiliation |
Fox Chase Cancer Center, Philadelphia, PA 19111, USA. Neal.Meropol@fccc.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
